Immunitybio completes acquisition of athenex's interest in dunkirk, new york advanced biotech manufacturing facility

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a clinical-stage immunotherapy company (“immunitybio”), today announced the successful completion of its acquisition of the leasehold interest in an iso class 5 pharmaceutical manufacturing space in western new york from global pharmaceutical company athenex, inc. (nasdaq: atnx). the new state-of-the-art biotech production facility, located in dunkirk, new york (chautauqua county), includes clean rooms for upstream and down
ATNX Ratings Summary
ATNX Quant Ranking